Anavex Life Sciences (AVXL) Accumulated Depreciation & Amortization (2010 - 2013)
Anavex Life Sciences recorded quarterly Accumulated Depreciation & Amortization of $192.0 in Q4 2013, down 66.67% quarter-over-quarter from $576.0 in Q3 2013, and down 58.71% year-over-year from $465.0 in Q4 2012.
Anavex Life Sciences' Accumulated Depreciation & Amortization history runs 4 years deep, the most recent figure standing at $192.0 for Q4 2013.
- In Q4 2013, Accumulated Depreciation & Amortization fell 58.71% year-over-year to $192.0; the TTM figure through Dec 2013 stood at $192.0 (down 58.71% YoY), while the FY2013 annual figure was $576.0, down 69.0% from the prior year.
- Accumulated Depreciation & Amortization came in at $192.0 for Q4 2013 at Anavex Life Sciences, down from $576.0 in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $1858.0 in Q3 2012 to a low of $111.0 in Q1 2013.
- A 4-year average of $743.36 and a median of $533.5 in 2010 frame the typical range for Accumulated Depreciation & Amortization.
- Across the five-year window, Accumulated Depreciation & Amortization jumped 269.76% in 2012 and slumped 88.05% in 2013, its largest moves.
- Anavex Life Sciences' Accumulated Depreciation & Amortization stood at $491.0 in 2010, then slipped by 5.5% to $464.0 in 2011, then advanced by 0.22% to $465.0 in 2012, then slumped by 58.71% to $192.0 in 2013.
- According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods registered $192.0, $576.0, and $576.0 for Q4 2013, Q3 2013, and Q2 2013 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 192.00 |
| Dec 31, 2013 | 192.00 |
| Sep 30, 2013 | 576.00 |
| Sep 30, 2013 | 576.00 |
| Jun 30, 2013 | 576.00 |
| Jun 30, 2013 | 576.00 |
| Mar 31, 2013 | 111.00 |
| Mar 31, 2013 | 111.00 |
| Dec 31, 2012 | 465.00 |
| Dec 31, 2012 | 465.00 |
| Sep 30, 2012 | 1,858.00 |
| Sep 30, 2012 | 1,858.00 |
| Jun 30, 2012 | 1,394.00 |
| Jun 30, 2012 | 1,394.00 |
| Mar 31, 2012 | 929.00 |
| Mar 31, 2012 | 929.00 |
| Dec 31, 2011 | 464.00 |
| Dec 31, 2011 | 464.00 |
| Sep 30, 2011 | 1,657.00 |
| Sep 30, 2011 | 1,657.00 |
| Jun 30, 2011 | 377.00 |
| Jun 30, 2011 | 377.00 |
| Mar 31, 2011 | 407.00 |
| Mar 31, 2011 | 407.00 |
| Dec 31, 2010 | 491.00 |
| Dec 31, 2010 | 491.00 |
| Sep 30, 2010 | 910.00 |
| Sep 30, 2010 | 910.00 |